EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
pharmaceutical investing Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
